Pinyadapat Aroonthongsawat

Pinyadapat Aroonthongsawat

Auto-generated profile, based on publicly available information

Pinyadapat Aroonthongsawat


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
PAPinyadapat Aroonthongsawat
Pinyadapat Aroonthongsawat
XFXue Feng
Xue Feng
YJYuxuan Ji
Yuxuan Ji
YXYuxiang Xue
Yuxiang Xue
NONurbanu Ozgultekin
Nurbanu Ozgultekin
YSYaneenart Suwanwong
Yaneenart Suwanwong
In this study, a multifunctional carrier-free nanoplatform composed of curcumin and indocyanine green self-assembled into uniform spherical nanoparticles, coated with polydopamine, and functionalized with anti-CD33 antibodies is used for targeted AML therapy. Indocyanine green drives stable co-assembly with curcumin, while the polydopamine layer improves photostability, enables pH-responsive release in acidic tumor-like environments, and provides versatile chemistry for antibody conjugation. CD33 targeting confers selective uptake via receptor-mediated endocytosis into AML cells. In vitro studies demonstrated that Ab@pDCur–ICG NPs achieved significantly higher uptake and cytotoxicity in CD33-positive cells than in CD33-negative controls, with uptake reduced upon antibody blocking. Under near-infrared irradiation, the nanoparticles produced synergistic chemo–photothermal effects, yielding the highest apoptotic response in CD33-positive leukemia cells. Notably, the formulation displayed high structural uniformity compared to typical carrier-free assemblies, supporting enhanced stability and reproducibility. This targeted, multimodal nanoplatform integrates high drug loading, selective delivery, and synergistic therapy, representing a promising strategy to improve AML outcomes and potentially extend to other hematological malignancies.

27 July 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
PAPinyadapat Aroonthongsawat
Pinyadapat Aroonthongsawat
XFXue Feng
Xue Feng
YJYuxuan Ji
Yuxuan Ji
YXYuxiang Xue
Yuxiang Xue
NONurbanu Ozgultekin
Nurbanu Ozgultekin
YSYaneenart Suwanwong
Yaneenart Suwanwong